Lifeloc Reports Second Quarter 2024 Results

Rhea-AI Summary

Lifeloc Technologies (OTC PINK:LCTC) reported Q2 2024 financial results with net revenue of $2.387 million, a 5% increase from Q2 2023. However, the company posted a net loss of $(298) thousand, or $(0.12) per diluted share, compared to a net income of $55 thousand in Q2 2023. Gross margin declined to 41.6% from 45.7% year-over-year. R&D investment increased by 67% to $662 thousand, primarily for SpinDx development.

The company highlighted progress in its L-series devices, including the launch of LX9 units with smartphone pairing. Lifeloc is focusing on developing the SpinDx technology platform for rapid drug detection, with beta testing planned for later in 2024 and commercial launch projected for 2025. To support development, Lifeloc secured a $750,000 line of credit and raised $798,000 through a private placement of shares.

Positive

• Net revenue increased by 5% year-over-year to $2.387 million in Q2 2024
• R&D investment rose 67% to $662 thousand, primarily for SpinDx development
• Launched LX9 units with smartphone pairing capability
• Secured $750,000 line of credit and raised $798,000 through private placement to support SpinDx development

Negative

• Reported net loss of $(298) thousand in Q2 2024, compared to net income of $55 thousand in Q2 2023
• Gross margin declined to 41.6% from 45.7% year-over-year
• Cash position decreased to $505 thousand at the end of Q2 2024
• Dilution of existing shareholders due to private placement of 210,000 new shares

WHEAT RIDGE, CO / ACCESSWIRE / August 8, 2024 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2024.

Second Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $2.387 million in the second quarter of 2024, resulting in a quarterly net loss of $(298) thousand, or $(0.12) per diluted share. These results compare to net revenue of $2.280 million and quarterly net income of $55 thousand, or $0.02 per diluted share in the second quarter of 2023. Revenue for the quarter increased 5% versus the second quarter last year. Six-month net revenues of $4.541 million and a net loss of $(582) thousand, or $(0.24) per diluted share, compared to net revenue of $4.445 million and a net profit of $1 thousand, or $0.00 per diluted share, for the same six months of 2023. Total gross margin in the second quarter declined to 41.6% versus 45.7% for the same quarter last year. For the first six months of 2024 gross margin was 40.3% versus 44.5% for the same period last year, with the decline due primarily to increases in costs resulting from inflation. The research and development investment of $662 thousand rose by 67% versus the second quarter last year, primarily for SpinDx development, contributing significantly to the current period loss.

We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that have driven market penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. Additionally, LX9 units capable of smart phone pairing began to ship in this quarter.

"We are excited to be able to offer and ship LX9 units with smart phone pairing to achieve better systems integration, which some customers have been seeking commented Dr. Wayne Willkomm, President and CEO. "This demonstrates again our commitment to innovation."

We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as SAI's (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and contributes to market share gains by the workplace Phoenix® 6.0 BT and EV 30 devices.

We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc's proven capability to build easy-to-use portable testing equipment. We are therefore focusing our research and development efforts on leveraging the SpinDx™ technology platform, sometimes referred to as "Lab on a Disk," to develop a series of devices and tests that can be used at roadside and in emergency rooms, forensic labs and workplace test sites to achieve a rapid and quantitative measure for a panel of drugs of abuse. The initial product release is projected to be a device with a disk that allows for detection of delta-9-THC (the major intoxicating component of the cannabis plant) from a test subject's saliva, followed by a disk for a panel of other drugs. SpinDx has been demonstrated in our laboratory to effectively detect for delta-9-THC, cocaine, fentanyl, amphetamine methamphetamine, morphine, MDMA, and benzodiazepines. Testing has validated the SpinDx measurement technology against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples. The LCMS data have validated the SpinDx test results on real-world human saliva tests at a limit of detection of approximately 10 ng/ml. With our research and development work, we continue to improve our technology's robustness, speed, and convenience of operation. We plan to start of beta testing of our SpinDx saliva testing system utilizing the delta-9-THC disks later in 2024 using prototype readers as shown in the photograph below. Commercial launch of our first SpinDx application is projected to occur in 2025. Following initial commercialization, we expect more offerings from this technology platform to include expanded drug panels and samples collected from blood and breath. Following the release of our SpinDx saliva testing system, we expect to accelerate development of combining our LX9 breathalyzer with the THC SpinDx detection unit, to produce our roadside marijuana breathalyzer system.

"Our top priority is pushing the SpinDx product platform across the finish line," Dr. Willkomm said. "We anticipate continued high research and development expenses in this final push toward commercialization. With the rising demand for saliva drug testing, the initial release of SpinDx to the market becomes more urgent and valuable."

Research and development expenditures for SpinDx completion have consumed cash down to $505 thousand at the end of the second quarter. In anticipation of declining cash, the company has sought to strengthen its financial resources. Early in the third quarter the Company closed on a $750,000 line of credit with Citywide Banks as well as a private placement of 210,000 shares of the Company's common stock at $3.80 per share, resulting in a $798,000 capital injection to assist the SpinDx development in moving forward to testing and commercialization.

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC:LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings.

Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets (Unaudited)

ASSETS

CURRENT ASSETS:		June 30, 2024				December 31, 2023
Cash and cash equivalents		$	504,642			$	1,766,621
Accounts receivable, net			831,501				812,126
Inventories, net			2,962,071				3,024,834
Federal and state income taxes receivable			40,280				-
Prepaid expenses and other			176,928				105,967
Total current assets			4,515,422				5,709,548
PROPERTY AND EQUIPMENT, at cost:
Land			317,932				317,932
Building			1,928,795				1,928,795
Real-time Alcohol Detection And Reporting equipment and software			569,448				569,448
Production equipment, software and space modifications			1,337,919				1,154,803
Training courses			432,375				432,375
Office equipment, software and space modifications			233,190				216,618
Sales and marketing equipment and space modifications			226,356				226,356
Research and development equipment, software and space modifications			544,933				480,684
Research and development equipment, software and space modifications not in service			227,354				-
Less accumulated depreciation			(3,435,629	)			(3,326,837	)
Total property and equipment, net			2,382,673				2,000,174
OTHER ASSETS:
Patents, net			82,422				64,439
Deposits and other			34,790				111,157
Deferred taxes			996,005				806,652
Total other assets			1,113,217				982,248
Total assets		$	8,011,312			$	8,691,970
CURRENT LIABILITIES:
Accounts payable		$	459,560			$	402,231
Term loan payable, current portion			52,386				51,588
Income taxes payable			-				44,952
Customer deposits			168,915				195,719
Accrued expenses			288,415				329,311
Deferred revenue, current portion			65,917				79,036
Reserve for warranty expense			46,500				46,500
Total current liabilities			1,081,693				1,149,337
TERM LOAN PAYABLE, net of current portion and
debt issuance costs			1,144,876				1,170,243
DEFERRED REVENUE, net of current portion			5,712				11,565
Total liabilities			2,232,281				2,331,145
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' EQUITY:
Common stock, no par value; 50,000,000 shares authorized, 2,454,116 shares
issued and outstanding as of June 30, 2024 and December 31, 2023			4,668,014				4,668,014
Retained earnings			1,111,017				1,692,811
Total stockholders' equity			5,779,031				6,360,825
Total liabilities and stockholders' equity		$	8,011,312			$	8,691,970

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Loss) (Unaudited)

		Three Months Ended June 30,
REVENUES:		2024				2023
Product sales		$	2,370,433			$	2,246,407
Royalties			8,824				10,150
Rental income			8,073				23,789
Total			2,387,330				2,280,346
COST OF SALES			1,393,734				1,237,902
GROSS PROFIT			993,596				1,042,444
OPERATING EXPENSES:
Research and development			662,276				395,781
Sales and marketing			365,374				300,075
General and administrative			363,008				284,116
Total			1,390,658				979,972
OPERATING INCOME (LOSS)			(397,062	)			62,472
OTHER INCOME (EXPENSE):
Interest income			8,677				19,200
Interest expense			(10,057	)			(10,290	)
Total			(1,380	)			8,910
NET INCOME (LOSS) BEFORE BENEFIT FROM (PROVISION FOR) TAXES			(398,442	)			71,382
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES			100,454				(16,237	)
NET INCOME (LOSS)		$	(297,988	)		$	55,145
NET INCOME (LOSS) PER SHARE, BASIC		$	(0.12	)		$	0.02
NET INCOME (LOSS) PER SHARE, DILUTED		$	(0.12	)		$	0.02
WEIGHTED AVERAGE SHARES, BASIC			2,454,116				2,454,116
WEIGHTED AVERAGE SHARES, DILUTED			2,454,116				2,454,116

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Loss) (Unaudited)

		Six Months Ended June 30,
REVENUES:		2024				2023
Product sales		$	4,504,867			$	4,379,766
Royalties			19,760				18,356
Rental income			16,146				46,778
Total			4,540,773				4,444,900
COST OF SALES			2,711,870				2,467,029
GROSS PROFIT			1,828,903				1,977,871
OPERATING EXPENSES:
Research and development			1,217,875				792,547
Sales and marketing			710,383				587,958
General and administrative			677,934				603,131
Total			2,606,192				1,983,636
OPERATING (LOSS)			(777,289	)			(5,765	)
OTHER INCOME (EXPENSE):
Interest income			26,349				29,000
Interest expense			(20,207	)			(20,825	)
Total			6,142				8,175
NET INCOME (LOSS) BEFORE BENEFIT FROM (PROVISION FOR) TAXES			(771,147	)			2,410
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES			189,353				(1,053	)
NET INCOME (LOSS)		$	(581,794	)		$	1,357
NET INCOME (LOSS) PER SHARE, BASIC		$	(0.24	)		$	-
NET INCOME (LOSS) PER SHARE, DILUTED		$	(0.24	)		$	-
WEIGHTED AVERAGE SHARES, BASIC			2,454,116				2,454,116
WEIGHTED AVERAGE SHARES, DILUTED			2,454,116				2,454,116

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Stockholders' Equity (Unaudited)

		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Total stockholders' equity, beginning balances		$	6,077,019			$	6,101,423			$	6,360,825			$	6,155,211
Common stock (no shares issued during periods):
Beginning balances			4,668,014				4,668,014				4,668,014				4,668,014
Ending balances			4,668,014				4,668,014				4,668,014				4,668,014
Retained earnings:
Beginning balances			1,409,005				1,433,409				1,692,811				1,487,197
Net income (loss)			(297,988	)			55,145				(581,794	)			1,357
Ending balances			1,111,017				1,488,554				1,111,017				1,488,554
Total stockholders' equity, ending balances		$	5,779,031			$	6,156,568			$	5,779,031			$	6,156,568

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Cash Flows (Unaudited)

			Six Months Ended June 30,
CASH FLOWS FROM OPERATING ACTIVITIES:			2024				2023
Net income (loss)			$	(581,794	)		$	1,357
Adjustments to reconcile net income (loss) to net cash
(used in) operating activities-
Depreciation and amortization				114,619				132,088
Provision for doubtful accounts, net change				(3,175	)			-
Provision for inventory obsolescence, net change				(35,000	)			-
Deferred taxes				(189,353	)			1,053
Changes in operating assets and liabilities-
Accounts receivable				(16,200	)			(134,751	)
Inventories				97,763				(171,601	)
Employee retention credit and income taxes receivable				(40,280	)			107,575
Prepaid expenses and other				(70,961	)			(149,575	)
Deposits and other				76,367				-
Accounts payable				57,329				(84,118	)
Income taxes payable				(44,952	)			-
Customer deposits				(26,804	)			(26,064	)
Accrued expenses				(40,896	)			(54,002	)
Deferred revenue				(18,972	)			(18,955	)
Net cash (used in)
operating activities				(722,309	)			(396,993	)
CASH FLOWS USED IN INVESTING ACTIVITIES:
Purchases of property and equipment				(263,937	)			(14,811	)
Purchases of research and development equipment, software
and space modifications not in service				(227,354	)			-
Patent filing costs				(21,708	)			(1,404	)
Net cash used in investing activities				(512,999	)			(16,215	)
CASH FLOWS USED IN FINANCING ACTIVITIES:
Principal payments made on term loan payable				(26,671	)			(26,047	)
Net cash used in financing
activities				(26,671	)			(26,047	)
NET (DECREASE) IN CASH				(1,261,979	)			(439,255	)
CASH, BEGINNING OF PERIOD				1,766,621				2,352,754
CASH, END OF PERIOD			$	504,642			$	1,913,499
SUPPLEMENTAL INFORMATION:
Cash paid for interest			$	18,105			$	18,673
Cash paid for income tax			$	40,280			$	-

CONTACT:

Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500

SOURCE: Lifeloc Technologies, Inc.

View the original press release on accesswire.com

FAQ

What were Lifeloc's (LCTC) Q2 2024 revenue and earnings?

Lifeloc reported Q2 2024 net revenue of $2.387 million and a net loss of $(298) thousand, or $(0.12) per diluted share.

How did Lifeloc's (LCTC) Q2 2024 results compare to Q2 2023?

Lifeloc's Q2 2024 revenue increased 5% year-over-year, but the company reported a net loss compared to a net income in Q2 2023.

What is Lifeloc's (LCTC) main focus for R&D investment?

Lifeloc is primarily investing in the development of the SpinDx technology platform for rapid drug detection.

When does Lifeloc (LCTC) plan to launch its SpinDx product commercially?

Lifeloc projects the commercial launch of its first SpinDx application to occur in 2025, with beta testing planned for later in 2024.